文献速递类风湿关节炎

早期对certolizumab pegol无反应预测类风湿关节炎1年未达低疾病活动度

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.
PubMed 文献 · RMD Open · 2020-01-01

基于ECLAIR前瞻性观察研究 interim 数据,评估活动性RA患者起始CZP治疗后3个月早期无反应对12个月未达LDA的预测价值。574/792例患者在M3接受治疗,CDAI无反应预测M12未达LDA的值为88.8%(95%CI 81.0-94.1),特异性96.0%。结论:M3时CDAI无反应可预测M12未达治疗目标LDA。

要点

  • M3时CDAI无反应预测M12未达LDA的值为88.8%(95%CI 81.0-94.1)。
  • CDAI无反应的特异性为96.0%,仅不足5%的M12应答者M3未应答。
  • DAS28(ESR)的预测性仅在基线高疾病活动和/或既往生物制剂治疗患者中相似。

核心结论

  • 在起始CZP治疗的RA患者中,M3时CDAI无反应可预测M12未达LDA。

研究设计与样本

  • ECLAIR为法国3年纵向、前瞻性、观察性、多中心研究,纳入活动性RA起始CZP治疗患者。
  • 本文为方案规定的interim数据分析,评估M3早期无反应对M12未达LDA的预测性。
  • 评估指标为CDAI、DAS28(ESR)和HAQ-DI;574/792例患者在M3接受治疗。
  • 可预测性分析可用例数:CDAI 532例、DAS28(ESR) 434例、HAQ-DI 496例。

主要发现

  • CDAI的预测值最高,为88.8%(95%CI 81.0-94.1),即M3无反应者中高达88%在M12未达LDA。
  • CDAI无反应预测不受基线疾病严重程度或治疗史影响。
  • CDAI无反应特异性为96.0%,即不足5%的M12 CDAI应答者M3未应答。
  • DAS28(ESR)预测性相似,但仅在基线高疾病活动和/或既往生物制剂治疗患者中。

关键数值与推荐

  • 早期无反应在M3测量,治疗失败定义为M12未达LDA。
  • CDAI无反应预测M12未达LDA的值88.8%(95%CI 81.0-94.1),特异性96.0%。

临床怎么用

  • 对起始CZP治疗的RA患者,M3时CDAI无反应可提示M12可能未达LDA。
  • M3 CDAI无反应可作为早期识别可能治疗失败患者的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the performance of clinical criteria for predicting late treatment failure in patients with early non-response to certolizumab pegol (CZP). METHODS: A protocol-specified analysis of interim data from ECLAIR, a 3-year longitudinal, prospective, observational, multicentre study of patients with active rheumatoid arthritis (RA) initiating CZP treatment in France, was conducted. Clinical measures assessed were Clinical Disease Activity Index (CDAI), Disease Activity Score-28 with erythrocyte sedimentation rate (DAS28(ESR)) and Health Assessment Questionnaire Disability Index (HAQ-DI). Early non-response was measured at 3 months (M3) and failure to achieve low disease activity (LDA) at 12 months (M12). RESULTS: 574/792 enrolled patients were treated at M3. The numbers available for predictability analyses were 532 (CDAI), 434 (DAS28(ESR)) and 496 (HAQ-DI). Of the three indices evaluated, the highest predictor of non-response value was observed for the CDAI (88.8% (95% CI 81.0 to 94.1)), indicating that up to 88% of patients identified as non-responders at M3 failed to achieve LDA at M12, regardless of baseline disease severity or treatment history. The specificity for this measure was also very high (96.0%), indicating that less than 5% of patients who achieved CDAI response at M12 had not responded at M3. Similar predictability was observed for DAS28(ESR), but only in patients with high disease activity at baseline and/or those previously treated by a biological disease-modifying antirheumatic drug. CONCLUSION: CDAI non-response at M3 is a predictor of failure to achieve the therapeutic target of LDA at M12 in patients with RA initiating treatment with CZP.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Saraux A, Flipo RM, Fagnani F, et al. Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. RMD Open. 2020. PMID: 31958276. doi:10.1136/rmdopen-2019-000991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。